ClinicalTrials.gg

Program

ACE723

A development code.

Its studies are mostly in Carcinoma, Hepatocellular, led by Acepodia Biotech.

Furthest: phase 1, since Sep 29, 20261 company-led study, 1 open or runningNext primary completion: May 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Acepodia Biotech11 open or runningphase 1since Sep 29, 2026Sep 29, 2026May 2030phase 1 · NCT07861425

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 29, 2026First study: phase 1 study in Carcinoma, HepatocellularFirst studyNCT07861425 · 70 planned · China

Ahead

  1. May 2030Primary completion: phase 1 study in Carcinoma, HepatocellularNCT07861425

TargetBeta

GPC3 →read by rule
“A Phase 1 Clinical Trial of ACE723, A Dual-Payload Antibody Drug Conjugate Targeting Glypican-3 (GPC-3), in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Who Have Failed or Progressed on Standard Immune Checkpoint Inhibitor-Containing Systemic Therapies”study text, by rule · the study

Other programs on GPC3

ProgramCompanyFurthest phaseStudies
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033ruleBeOne Medicinesphase 33
codrituzumabHoffmann-La Rochephase 23
GPC3-targeted Plasmid DNA Vaccine NWRD06ruleNewish Biotech (Wuxi)phase 22
Actinium Ac 225 GPC3-targeted Peptide RYZ801Bristol-Myers Squibbphase 21
Anti-GPC3 T Cell-engaging Antibody AZD9793AstraZenecaphase 21
Anti-GPC3 Antibody-drug Conjugate ZW251ruleZymeworksphase 11
Anti-GPC3 Antibody-drug Conjugate ABBV-324AbbViephase 11
Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926ruleBayerphase 11
TQB6426ruleSino Biopharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07861425Carcinoma, Hepatocellular · China1Not yet recruitingMay 203070

How it is read

Names in the registry

  • “ACE723”, 1 entry

Codes read as this program: ACE723.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.